Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 29, Issue 7, 2013, Pages 1019-1025

  Koethe, John R ^a   Dee, Kevin ^a   Bian, Aihua ^a   Shintani, Ayumi ^a   Turner, Megan ^a   Bebawy, Sally ^a   Sterling, Timothy R ^a   Hulgan, Todd ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; SOLUBLE CD14; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPETENT CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD14; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHEMOKINE CCL3; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETROSPECTIVE STUDIES; SOLUBILITY;

EID: 84879189550     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0016     Document Type: Article

References (39)

1. Amorosa V, Synnestvedt M, Gross R, et al.: A tale of 2 epidemics: The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005;39(5):557-561.
2. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, and Ganesan A: Obesity among patients with HIV: The latest epidemic. AIDS Patient Care STDS 2008;22(12):925-930.
3. Lakey WC, Yang LY, Yancy W, Chow SC, and Hicks CB: From wasting to obesity: Initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses 2013;29(3):435-440.
4. Kim DJ, Westfall AO, Chamot E, et al.: Multimorbidity patterns in HIV-infected patients: The role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012;15; 61(5):600-605.
5. Prospective Studies Collaboration, Whitlock G, Lewington S, et al.: Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet 2009;373(9669):1083-1096.
6. National Heart L, and Blood Institute (NHLBI): The Evidence Report: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD. NIH Publication No. 98-4083, 1998.
7. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, and McComsey GA: Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010;33(10):2244-2249.
8. Triant VA, Meigs JB, and Grinspoon SK: Association of Creactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51(3):268-273.
9. Kuller LH, Tracy R, Belloso W, et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5(10):e203.
10. Samaras K, Gan SK, Peake PW, Carr A, and Campbell LV: Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity (Silver Spring) 2009;17(1):53-59.
11. Koethe JR, Bian A, Shintani AK, et al.: Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. AIDS Res Hum Retroviruses 2012;28(6):552-557.
12. Reingold J, Wanke C, Kotler D, et al.: Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008;48(2):142-148.
13. Skurk T, Alberti-Huber C, Herder C, and Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92(3):1023-1033.
14. Bruun JM, Lihn AS, Pedersen SB, and Richelsen B: Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): Implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005;90(4):2282-2289.
15. Jernas M, Palming J, Sjoholm K, et al.: Separation of human adipocytes by size: Hypertrophic fat cells display distinct gene expression. FASEB J 2006;20(9):1540-1542.
16. Duprez DA, Neuhaus J, Kuller LH, et al.: Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012;7(9):e44454.
17. Sandler NG, Wand H, Roque A, et al.: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203(6):780-790.
18. Boger MS, Shintani A, Redhage LA, et al.: Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: A longitudinal study. J Acquir Immune Defic Syndr 2009; 52(4):480-487.
19. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, and Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12):1796-1808.
20. Cancello R, Henegar C, Viguerie N, et al.: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54(8):2277-2286.
21. Lee YH, Nair S, Rousseau E, et al.: Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: Increased expression of inflammation-related genes. Diabetologia 2005;48(9):1776-1783.
22. Lihn AS, Richelsen B, Pedersen SB, et al.: Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: Implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285(5):E1072- 1080.
23. Bastard JP, Caron M, Vidal H, et al.: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359(9311):1026-1031.
24. Jan V, Cervera P, Maachi M, et al.: Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004;9(4):555-564.
25. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371.
26. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, and Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249(4975): 1431-1433.
27. Ulevitch RJ and Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13:437-457.
28. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, and Zimmerli W: Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun 1996;64(5):1762-1769.
29. Viardot A, Heilbronn LK, Samocha-Bonet D, Mackay F, Campbell LV, and Samaras K: Obesity is associated with activated and insulin resistant immune cells. Diabetes Metab Res Rev 2012;28(5):447-454.
30. Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, and Yki-Jarvinen H: Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2008;295(1):E85-91.
31. Canque B, Rosenzwajg M, Gey A, Tartour E, Fridman WH, and Gluckman JC: Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood 1996;87(5):2011-2019.
32. Annunziato F, Galli G, Nappi F, et al.: Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta. Blood 2000;95(4):1167-1174.
33. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, and Baggiolini M: Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 1995;25(1):64-68.
34. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270(5243):1811- 1815.
35. Scarlatti G, Tresoldi E, Bjorndal A, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokinemediated suppression. Nat Med 1997;3(11):1259-1265.
36. McKenzie SW, Dallalio G, North M, Frame P, and Means RT Jr: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996;10(9):F29-33.
37. Krowka JF, Gesner ML, Ascher MS, and Sheppard HW: Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 1997;85(1):21-27.
38. Ye P, Kazanjian P, Kunkel SL, and Kirschner DE: Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med 2004;143(5):310-319.
39. Buchacz K, Baker RK, Palella FJ Jr, et al.: Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther 2013;18(1):65-75. Allergy and Infectious Diseases Complementary and Alternative Medicine